{
  "id": 12353081,
  "title": "Mizuho reiterates Alector stock rating at Neutral on Roche deal",
  "url": "https://urgent.news/2026/10/06/mizuho-reiterates-alector-stock-rating-at-neutral-on-roche-deal",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T10:06:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/mizuho-reiterates-alector-stock-rating-at-neutral-on-roche-deal-93CH-4933818"
  },
  "original_language": "en",
  "account": "Mizuho has maintained a Neutral rating and a $1.50 price target on Alector Inc. (NASDAQ: ALEC) following the company's announcement of a partnership with Genentech, a subsidiary of Roche. The stock is currently trading at $1.99, which is above the analyst's target, with a market capitalization of $222 million. The agreement involves AL050, a preclinical blood-brain-barrier technology-enabled GCase enzyme replacement therapy for Parkinson's disease. This partnership provides Alector with significant pharmaceutical validation and cash flow. However, Alector has been experiencing an 83% revenue decline and is currently operating with a negative free cash flow of $158 million over the past year, according to InvestingPro data. Mizuho sees this as an opportunity for Alector to move into a new phase (\"Alector v2.0\") following prior late-stage clinical disappointments. The firm remains optimistic about the potential of blood-brain-barrier-enabled drug candidates.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}